Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Factors Affecting Drug Biotransformation: Biological01:19

Factors Affecting Drug Biotransformation: Biological

Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-Nucleus Multiomic Analysis Reveals Immune-Metabolic Reprogramming Consistent With Maladaptive Trained Immunity in HIV-Associated Neurocognitive Disorders.

Glia·2026
Same author

HIV-1 Nef generates lasting innate immune memory in haematopoietic stem and progenitor cells in vivo.

EMBO reports·2026
Same author

Maladaptive Trained Immunity Drives Persistent IL-6 Production and Enhanced TLR Responsiveness in Monocyte-Derived Macrophages from People Living with HIV.

Microorganisms·2026
Same author

Structural and functional modifications of neuronal lipid rafts: implications for HIV-associated neurological disorders.

Journal of neuroinflammation·2026
Same author

Corrigendum to: "Australian Atherosclerosis Society Position Statement on Lipoprotein(a): Clinical and Implementation Recommendations" [Heart Lung Circ. 32(3) (2023) 287-296.].

Heart, lung & circulation·2026
Same author

Targeting the ARF6-dependent recycling pathway to alter lipid rafts and reduce inflammation.

Journal of lipid research·2025

Related Experiment Video

Updated: Jul 16, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Genetic factors affecting HDL levels, structure, metabolism and function.

Dmitri Sviridov1, Paul J Nestel

  • 1Baker Heart Research Institute, Melbourne, Victoria, Australia. Dmitr.Sviridov@Baker.edu.au

Current Opinion in Lipidology
|March 14, 2007
PubMed
Summary

Genetic factors significantly influence high-density lipoprotein (HDL) levels, impacting cardiovascular disease risk. Understanding these genetic determinants, alongside environmental interactions, is key to predicting and managing atherosclerosis.

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

Related Experiment Videos

Last Updated: Jul 16, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

Area of Science:

  • Cardiovascular Genetics
  • Lipid Metabolism
  • Atherosclerosis Research

Background:

  • High-density lipoprotein (HDL) is a key negative risk factor for cardiovascular diseases.
  • Identifying genetic determinants of HDL is crucial for cardiovascular risk prediction and understanding underlying biochemical mechanisms.

Purpose of the Study:

  • To review various approaches for establishing the genetic determinants of HDL concentration, structure, and function.
  • To elucidate the genetic contributions to HDL metabolism and its role in cardiovascular health.

Main Methods:

  • Review of existing literature on genetic associations with HDL.
  • Analysis of candidate gene polymorphisms and their impact on HDL levels.
  • Examination of gene-environment interactions influencing HDL.

Main Results:

  • Multiple genes contribute to HDL variability, but individual polymorphisms have a minor effect.
  • APOA1 and ABCA1 show the strongest influence on HDL concentrations and atherosclerosis risk.
  • CETP and lipases impact HDL functionality, with atherosclerosis risk dependent on gene-environment interactions.

Conclusions:

  • Analyzing genetic determinants in specific disease states or environmental contexts offers a more accurate assessment of HDL variations.
  • Defining gene-environment interaction rules can elucidate mechanisms behind HDL concentration and functionality variations.
  • This research aids in understanding HDL's role in cardiovascular health and disease prevention.